Publication: Chronic pulmonary aspergillosis following nontuberculous mycobacterial infections: An emerging disease
Issued Date
2020-12-01
Resource Type
ISSN
2309608X
Other identifier(s)
2-s2.0-85097610597
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Fungi. Vol.6, No.4 (2020), 1-10
Suggested Citation
Pakpoom Phoompoung, Methee Chayakulkeeree Chronic pulmonary aspergillosis following nontuberculous mycobacterial infections: An emerging disease. Journal of Fungi. Vol.6, No.4 (2020), 1-10. doi:10.3390/jof6040346 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/60337
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Chronic pulmonary aspergillosis following nontuberculous mycobacterial infections: An emerging disease
Author(s)
Other Contributor(s)
Abstract
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. Chronic pulmonary aspergillosis (CPA) following nontuberculous mycobacterial (NTM) lung disease is being increasingly recognized, especially in countries where tuberculosis is not endemic, with an incidence rate of 3.9–16.7%. NTM lung disease has been identified as a predictor of mortality in CPA patients. The major risk factors for NTM-associated CPA include fibrocavitary NTM lung disease, the presence of pulmonary emphysema, and high-dose corticosteroid use. The onset of CPA is 1.5–7 years following the diagnosis of NTM lung disease. The diagnosis can be made using standard criteria; however, serological diagnosis using Aspergillus precipitin has demonstrated a higher sensitivity and specificity when compared with fungal culture from respiratory specimens. Treatment is challenging since rifampicin and oral triazoles should not be used concomitantly. The prognosis is poor, and the factors associated with worse prognosis are corticosteroid use and high C-reactive protein level.